Accera Inc. (Broomfield, Colo.), a healthcare company focused on acute and chronic neurodegenerative diseases, will receive investment from NestlÃ© Health Science SA (Vevey, Switzerland) to develop and commercialize Axona, a prescription medical food for mild to moderate Alzheimer’s Disease (AD). Luis Cantarell, president and CEO of NestlÃ© Health Science, will join Accera’s board of directors. According to the Axona website, AD patients suffer a dramatic drop in the brain’s ability to metabolize glucose; Axona addresses energy deficiencies in the brain by providing an alternative source of energy. In clinical trials, patients on Axona experienced cognitive improvement in 45 days. NestlÃ© Health Science is focused on developing science-based personalized nutritional solutions for chronic medical conditions.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news.